Collegium Pharmaceutical, Inc. (COLL)
24.75
+0.54
(+2.23%)
USD |
NASDAQ |
Nov 09, 10:09
Collegium Pharmaceutical Profit Margin (Quarterly) : 10.06% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 10.06% |
| June 30, 2026 | -7.53% |
| March 31, 2026 | 7.49% |
| December 31, 2025 | 8.26% |
| September 30, 2025 | 15.05% |
| June 30, 2025 | 6.37% |
| March 31, 2025 | 1.36% |
| December 31, 2024 | 6.89% |
| September 30, 2024 | 5.86% |
| June 30, 2024 | 13.50% |
| March 31, 2024 | 19.12% |
| December 31, 2023 | 21.33% |
| September 30, 2023 | 15.09% |
| June 30, 2023 | 9.60% |
| March 31, 2023 | -12.04% |
| December 31, 2022 | -5.55% |
| September 30, 2022 | 0.36% |
| June 30, 2022 | -4.20% |
| March 31, 2022 | -15.60% |
| December 31, 2021 | -91.49% |
| September 30, 2021 | 10.21% |
| Date | Value |
|---|---|
| June 30, 2021 | 87.82% |
| March 31, 2021 | 17.85% |
| December 31, 2020 | 9.12% |
| September 30, 2020 | 14.25% |
| June 30, 2020 | 10.32% |
| March 31, 2020 | 0.59% |
| December 31, 2019 | -2.97% |
| September 30, 2019 | -8.38% |
| June 30, 2019 | -6.28% |
| March 31, 2019 | -13.02% |
| December 31, 2018 | 12.37% |
| September 30, 2018 | -23.52% |
| June 30, 2018 | -17.88% |
| March 31, 2018 | -29.26% |
| December 31, 2017 | -161.2% |
| September 30, 2017 | -111.0% |
| June 30, 2017 | -593.3% |
| March 31, 2017 | -1.06K% |
| December 31, 2016 | -2.12K% |
| September 30, 2016 | -6.48K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 11.25% |
| Corcept Therapeutics, Inc. | 36.56% |
| Veru, Inc. | -- |
| Johnson & Johnson | 0.83% |
| Eli Lilly & Co. | 26.44% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 12.75% |
| Return on Assets | 2.08% |
| Return on Invested Capital | 2.84% |
| Gross Profit Margin (Quarterly) | 57.97% |
| Operating Margin (Quarterly) | 12.38% |
| Return on Net Operating Assets | 2.71% |